Icon

ONSOLIS (nda022266)- (EQ 0.2MG BASE,EQ 0.4MG BASE,EQ 0.6MG BASE,EQ 0.8MG BASE,EQ 1.2MG BASE)

FENTANYL CITRATE ADALVO
EQ 0.2MG BASE,EQ 0.4MG BASE,EQ 0.6MG BASE,EQ 0.8MG BASE,EQ 1.2MG BASE
No Yes
2027-Jul-23 Expired
None 2012-Jul-16
None No
ONSOLIS is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 0.2MG BASE ** ** - - -
EQ 0.4MG BASE ** ** - - -
EQ 0.6MG BASE ** ** - - -
EQ 0.8MG BASE ** ** - - -
EQ 1.2MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.